Related Experiment Video

Updated: Aug 25, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases

Carlos García-Echeverría1, Doriano Fabbro

  • 1Oncology Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. carlos.garcia-echeverria@pharma.novartis.com

Mini Reviews in Medicinal Chemistry
|March 23, 2004
PubMed

Insights

Targeting receptor protein tyrosine kinases (RPTKs) is a promising cancer chemotherapy strategy. New RPTK inhibitors show improved potency and efficacy, with many in clinical trials or late-stage development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor protein tyrosine kinases (RPTKs) play a crucial role in cancer development and progression.
  • Growing evidence links specific RPTKs to various solid and liquid tumors.
  • Understanding oncogenic activation of RPTKs is key to developing targeted therapies.

Purpose of the Study:

  • To review the current landscape of receptor protein tyrosine kinase (RPTK) inhibitors.
  • To highlight promising RPTK inhibitors in clinical trials and late-stage preclinical development.
  • To provide an overview of advancements in RPTK-targeted cancer chemotherapy.

Main Methods:

  • Literature review of preclinical and clinical data on RPTK inhibitors.
  • Summary of current knowledge on RPTK inhibitors in clinical trials.
  • Identification of RPTK inhibitors in late-stage preclinical development.

Main Results:

  • Preclinical and clinical data confirm the involvement of RPTKs in tumorigenesis.
  • New classes of RPTK inhibitors demonstrate significant improvements in potency, specificity, and efficacy.
  • Several promising RPTK inhibitors are advancing through clinical trials and preclinical development.

Conclusions:

  • Targeting RPTKs represents a compelling strategy for cancer chemotherapy.
  • Advancements in kinase inhibitor development offer enhanced therapeutic potential.
  • The reviewed RPTK inhibitors show promise for future cancer treatment applications.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...